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Abstract In Japan, only a few antifungal agents have
been approved for children, but in actual clinical practice,
various antifungal agents used in adults are administered to
pediatric patients with invasive fungal infections (IFIs).
However, the pediatric dosages of some antifungal agents
are not indicated in the package inserts or mentioned in the
Japanese Mycology Study Group 2007 Guidelines for
Management of Deep-seated Mycoses. We conducted a
nationwide survey to determine how antifungal agents are
being used to treat pediatric patients with IFIs in Japan. We
sent a questionnaire to 792 medical centers that train
pediatricians and received 250 (31.6 %) responses. In the
past 5 years, 65 (26.0 %) of 250 facilities reported treating
a total of 232 cases of IFIs. The characteristics of pediatric
patients with IFIs were almost the same as adult patients
except that immunological diseases and neonatal diseases
are common as underlying diseases. Antifungal agents used
in adults were all used in children. However, the dosages of
some antifungal agents deviated from the package insert or
guideline recommendations. As for the reasons for select-
ing a particular antifungal agent, strong antifungal activity
(including potency, broad spectrum, and clinical efﬁcacy)
was favored over safety. These results can be used to revise
guidelines for the management of children with IFIs.
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Introduction
Invasive fungal infections (IFIs) are a major cause of
morbidity and mortality in immunocompromised patients
[1–3]. IFIs often occur in children with various reasons for
increased susceptibility to infections, including immature
immune systems [4, 5]. Recently, the incidence of IFIs in
children has increased with expanded pediatric use of
therapies such as intensive chemotherapy, hematopoietic
stem cell transplantation, or both for leukemia, and
immunotherapy with steroids or immunosuppressants [6].
Early diagnosis of IFIs is challenging in children, not only
because there are few characteristic symptoms in patients
with severe underlying diseases, but also because of the
invasive nature of diagnostic examinations for IFIs [7].
Although several new antifungal agents have been devel-
oped during the past decade, not all of these agents have
been approved for children in Japan. Accordingly, the
pediatric dosages of some antifungal agents are not indi-
cated in their package inserts, and they are not mentioned
in the Japanese Mycology Study Group 2007 [8] Guide-
lines for Management of Deep-seated Mycoses (Japanese
guideline). We thought it was necessary to determine the
actual status of antifungal agent usage in children.
The present survey was conducted to determine how
antifungal agents are being used to treat pediatric patients
with IFIs in Japan. The results can be used to revise
guidelines for management of children with IFIs.
Patients and methods
A questionnaire with the following three questions was sent
to medical centers that train pediatricians in September
2009:
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(1-1) Have you treated pediatric patients with IFIs in the
last 5 years?
(1-2) If yes, which speciﬁc diseases?
(2-1) Which antifungal agents do you use typically?
(2-2) What is the usual dosage?
(3) In general, what are the reasons for selecting a
particular antifungal agent? Multiple answers were
allowed from the following choices: (a) strong anti-
fungal activity, (b) broad antifungal spectrum, (c) fungi-
cidal activity, (d) no drug-resistant strains, (e) high
clinical efﬁcacy, (f) high clinical safety, (g) recommen-
dation by a guideline, (h) abundant evidence, (j) indica-
tion in children, (k) considerable experience, (l) others.
The study protocol was approved by the Ethics Com-
mittee of Yokohama City University.
Results
The questionnaire was sent to 792 medical centers that
train pediatricians with 250 (31.6 %) replies. In the past
5 years, 65 of 250 (26.0 %) facilities reported treating a
total of 232 IFI cases, whereas 185 facilities (74.0 %)
reported no patients with IFIs. There was a variety of
answers to the question about speciﬁc infections. They
were classiﬁed into three categories, including underlying
diseases, diagnoses, and causative organisms (Table 1).
The underlying diseases for pediatric patients with IFIs
included hematological diseases (25 patients), immuno-
logical diseases (9 patients), neonatal diseases (6 patients),
and others (6 patients). Leukemia was the most common
underlying disease, followed by congenital immunodeﬁ-
ciency diseases. Neonatal or premature status were also
common. The major diagnosis of IFIs was sepsis (23
patients), followed by pneumonia (13 patients) and inva-
sive pulmonary aspergillosis (10 patients). The main
causative organisms were Candida spp. (25 patients) and
Aspergillus spp. (25 patients). Nine (36.0 %) of 25 Can-
dida spp. were further identiﬁed as Candida parapsilosis (3
cases), Candida tropicalis (3 cases), Candida albicans (2
cases), and Candida glabrata (1 case). None of the
Aspergillus spp. were further identiﬁed.
For each antifungal agent, questionnaire answers for the
dose typically used for prophylaxis and treatment of IFIs in
children were compared with recommendations for the
diagnosis and treatment of pediatric patients with IFIs in
the Japanese guideline [8] and the Infectious Diseases
Society of America (IDSA) guidelines on aspergillosis
(2008) [10] and candidiasis (2009) [11] (IDSA guidelines),
as well as the dosages described in each package insert in
Japan (Table 2).
Table 1 Characteristics of pediatric patients with IFIs
Underlying diseases N Diagnoses N Causative organisms N
Hematological diseases 25 Sepsis 23 Candida spp. 25
Leukemia 13 Pneumonia 13 Candida parapsilosis 3
Malignant lymphoma 4 Invasive pulmonary aspergillosis 10 Candida tropicalis 3
Solid tumor 3 Brain abscess 4 Candida albicans 2
Febrile neutropenia 3 Meningitis 3 Candida glabrata 1
Hematopoietic stem cell transplantation 2 Disseminated candidiasis 3 Unidentiﬁed 16
Immunological diseases 9 Pulmonary mycosis 2 Aspergillus spp. 25
Congenital immunodeﬁciency disease 7 Spleen abscess 2 Unidentiﬁed 25
Hemophagocytic syndrome 1 Endocarditis 2 Zygomycetes 3
Systemic juvenile idiopathic arthritis 1 Pulmonary embolism 1 Mucor sp. 1
Neonatal diseases 6 Lung abscess 1 Unidentiﬁed 2
Extremely low birth weight infant 3 Intermuscular abscess in extremities 1 Trichosporon beigelii 1
Low birth weight infant 1 Arthritis 1 Pneumocystis sp. 1
Neonatal necrotizing enterocolitis 1 Unidentiﬁed 1
Perforation of the digestive tract 1
Others 6
Congenital nephrosis 1
Peritoneal dialysis 1
Peritonitis 1
Acute encephalopathy 1
Hypoxemia 1
Near-drowning 1
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Micafungin
There were 20 facilities administering micafungin for
prophylaxis, almost half of the 45 facilities administering it
for treatment. The mean daily dose of micafungin used for
prophylaxis was 2.7 mg/kg, higher than the package insert
dosage. On the other hand, the mean daily dose of mica-
fungin for treatment was 4.6 mg/kg, which was in accord
with the Japanese guideline but was slightly higher than
IDSA guidelines recommendations.
Fluconazole
The number of facilities administering ﬂuconazole for
prophylaxis (40 facilities) and for treatment (42 facilities)
was almost the same. The mean daily dose of ﬂuconazole
used for prophylaxis was 6.4 mg/kg, higher than the dosage
recommended by the Japanese guideline. On the other
hand, the mean daily dose of ﬂuconazole used for treatment
was 8.9 mg/kg, slightly lower than the Japanese guideline
dose but in accordance with IDSA guidelines.
Fosﬂuconazole
The number of facilities administering fosﬂuconazole for
prophylaxis (40 facilities) and for treatment (42 facilities)
was almost the same, as with ﬂuconazole. The mean daily
dose of fosﬂuconazole used for prophylaxis was 6.7 mg/kg,
higher than the Japanese guideline recommendation.
However, the mean daily dose of fosﬂuconazole used for
treatment was 8.0 mg/kg, slightly lower than the Japanese
guideline dose.
Voriconazole
Voriconazole was most often administered for treatment
(39 facilities), not for prophylaxis (5 facilities). The mean
daily dose of voriconazole used for prophylaxis was
3.5 mg/kg. The mean daily dose of voriconazole used for
treatment was 7.6 mg/kg, which was in accordance with
IDSA guidelines.
Itraconazole
The number of facilities administering itraconazole for
prophylaxis (22 facilities) and for treatment (14 facilities)
was almost the same, but not as high as ﬂuconazole. The
mean daily dose of itraconazole used for prophylaxis was
4.2 mg/kg. The mean daily dose of itraconazole used for
treatment was 6.2 mg/kg.
Liposomal amphotericin B
Liposomal amphotericin B was mostly used for treatment
(33 facilities) rather than for prophylaxis (2 facilities).
The mean daily dose of liposomal amphotericin B used
for prophylaxis was 2.3 mg/kg. The mean daily dose of
liposomal amphotericin B used for treatment was
Table 2 Usages and dosage of antifungal agents in pediatric patients
Antifungal agents Usage Facilities
reporting use (I)
Dosage mean
(range)
(mg/kg)
Japanese
guideline
(mg/kg)
IDSA
guidelines
(mg/kg)
Dosage in Japanese
package insert (mg/kg)
Micafungin Prophylaxis 20 2.7 (1–4.5) 1
Treatment 45 4.6 (1–7) 3–6 2–4 1–6
Fluconazole Prophylaxis 40 6.4 (1.5–10) 3–6 12
Treatment 42 8.9 (6–10) 10–12 6–12a 3–12
Fosﬂuconazole Prophylaxis 40 6.7 (1.5–10)
Treatment 42 8 (4.5–10) (FLCZ: 100–400 mg)c
Voriconazole Prophylaxis 5 3.5 (3–6)
Treatment 39 7.6 (4–16) 7 (3–6)c
Itraconazole Prophylaxis 22 4.2 (1–7.5) (200–400 mg)c
Treatment 14 6.2 (4–10) (200–400 mg)c
Liposomal amphotericin B Prophylaxis 2 2.3 (2–2.5)
Treatment 33 4.1 (1–5.5) 3–5b (2.5–5)c
Amphotericin B
deoxycholate
Prophylaxis 13 0.75 (0.75)
Treatment 10 0.8 (0.5–1) 0.25–1 0.5–1a (0.25–1)c
a Recommended as primary therapy in neonatal candidiasis
b Recommended as alternative therapy in neonatal candidiasis
c The dosage for adults
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4.1 mg/kg, which was in accordance with IDSA
guidelines.
Amphotericin B deoxycholate
The number of facilities administering amphotericin B
deoxycholate for prophylaxis (13 facilities) and for treat-
ment (10 facilities) was almost the same, but not as high as
ﬂuconazole and itraconazole. The mean daily dose of
amphotericin B deoxycholate used for prophylaxis was
0.75 mg/kg. The mean daily dose of amphotericin B
deoxycholate for treatment was 0.8 mg/kg, which was in
accordance with both Japanese and IDSA guidelines.
The reasons for selecting a particular antifungal agent
are shown in Table 3. The most frequent response was
‘‘strong antifungal activity,’’ followed by ‘‘broad antifungal
spectrum’’ and ‘‘high clinical efﬁcacy,’’ all of which were
qualities related to antifungal activity. The next most fre-
quent response was ‘‘high clinical safety,’’ which was
followed by ‘‘considerable experience,’’ ‘‘recommendation
by a guideline,’’ and ‘‘abundant evidence.’’ ‘‘Indication for
children’’ was a very uncommon reason given.
Discussion
We conducted a nationwide survey to identify how anti-
fungal agents are being used to treat pediatric patients with
IFIs in Japan. In our survey, 65 (31.6 %) of 250 facilities
reported treating a total of 232 cases of pediatric IFIs in the
past 5 years.
As in adults, hematological diseases were the predomi-
nant underlying condition in children, although immuno-
deﬁciency and neonatal or premature status were also
common and unique to pediatric patients, compared to the
data on visceral mycoses found at autopsy cases in Japan
[11]. The major diagnosis of IFIs was sepsis, followed by
pneumonia and invasive pulmonary aspergillosis. The main
causative organisms were Candida spp. and Aspergillus
spp., at approximately equal frequencies. The major diag-
noses and causative organisms in children were also the
same as for adults [11].
At the time of the survey (September 2009), only two
antifungals, micafungin and liposomal amphotericin B, had
been approved for pediatric use in Japan (ﬂuconazole was
approved in 2011). On the other hand, antifungal agents
recommended by the Japanese guideline were ﬂuconazole,
itraconazole, amphotericin B deoxycholate, and micafun-
gin [8], and the IDSA guidelines recommended ﬂuconaz-
ole, voriconazole, amphotericin B deoxycholate, liposomal
amphotericin B, and micafungin [9]. Our survey indicated
that the antifungal agents not approved for pediatric use
and not recommended by Japanese or IDSA guidelines
were actually frequently used in clinical practice in Japan.
The antifungal agents most frequently used for pro-
phylaxis were ﬂuconazole and fosﬂuconazole, followed by
itraconazole, micafungin, and amphotericin B deoxycho-
late. Dosages of ﬂuconazole and fosﬂuconazole were
slightly higher than those recommended by the Japanese
guideline. This practice may result from the assumption
that the causative organism could be a non-albicans Can-
dida sp., which was substantiated by our observation that a
non-albicans Candida sp. was more frequently identiﬁed
than Candida albicans as the causative pathogen (Table 1).
The dose of micafungin used for prophylaxis was higher
than that recommended by the Japanese guideline, possibly
from the assumption that Aspergillus spp. could be
involved in IFIs.
The most frequently used antifungal agent for treatment
was micafungin, followed by fuluconazole/fosﬂuconazole,
voriconazole, and liposomal amphotericin B. Doses of
micafungin and liposomal amphotericin B were in accor-
dance with the Japanese and IDSA guidelines, respectively.
The IDSA guidelines suggest 10–12 mg/kg micafungin for
neonates [10]. In this survey, such a high dosage of mi-
cafungin was not reported. The doses of ﬂuconazole
(8.9 mg/kg) and fosﬂuconazole (8 mg/kg) were slightly
lower than the 10–12 mg/kg recommended by the Japanese
guideline for treatment, which is based on the assumption
that 3–6 mg/kg ﬂuconazole/fosﬂuconazole has been used
for prophylaxis. Actually, if fulconazole or fosﬂuconazole
is not effective, then it may be switched to other antifungal
agents. The dose of voriconazole used by survey respon-
dents was almost the same as that recommended by the
IDSA guideline [10], where administration of 7 mg/kg
voriconazole every 12 h is comparable to the adult dosage
of 4 mg/kg every 12 h.
In this survey, the respondents seemed to consider
antifungal activity more important than safety, probably
Table 3 Reasons for selection of antifungal agents
Reasons N
Strong activity 44
Broad spectrum 33
Fungicidal activity 11
No drug-resistant strains 4
High clinical efﬁcacy 36
High clinical safety 30
Recommendation by a guideline 23
Abundant evidence 17
Indication for children 14
Considerable experience 26
Others 4
No response 8
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because the conditions of pediatric patients being treated
with antifungal agents were quite severe.
This survey suggests that the Japanese guideline needs
to be revised. It also suggests that antifungal agents are
commonly being used without approval for this age group.
Both medical staff and pharmaceutical companies should
make efforts to obtain the approval of all antifungal agents
for pediatric use.
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